Sutro Biopharma, Inc. (STRO) Tops Q2 EPS by 27c

Sutro Biopharma, Inc. (NASDAQ: STRO) reported Q2 EPS of ($0.14), $0.27 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $63.74 million versus the consensus estimate of $15.79 million.

For earnings history and earnings-related data on Sutro Biopharma, Inc. (STRO) click here.

You May Also Be Interested In

• Securitize Corp (SECZ) PT Raised to $12 at StoneX on 'Innovation Exemption'
• salesforce.com (CRM) Reiterated at Market Outperform by Citizens on 'Significant Upside' Potential
• Magnitude International regains Nasdaq filing compliance